Hangzhou Tigermed Consulting Co., Ltd.

HNGZY · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$448$2,025$2,272$3,392
Dep. & Amort.$324$306$265$189
Deferred Tax$0-$14-$8$44
Stock-Based Comp.$0$0$47$83
Change in WC-$268-$849-$699-$191
Other Non-Cash$594-$274-$527-$2,093
Operating Cash Flow$1,097$1,150$1,358$1,424
Investing Activities
PP&E Inv.-$357-$314-$449-$369
Net Acquisitions-$367-$357-$663-$251
Inv. Purchases-$6,176-$2,142-$2,203-$3,188
Inv. Sales/Matur.$2,151$1,174$430$1,063
Other Inv. Act.$10-$257$95-$38
Investing Cash Flow-$4,739-$1,896-$2,789-$2,783
Financing Activities
Debt Repay.-$501$684$1,489$492
Stock Issued$0$0$24$24
Stock Repurch.-$271-$30-$427-$516
Dividends Paid-$642-$590-$432-$262
Other Fin. Act.-$289-$72$180-$394
Financing Cash Flow-$1,702-$8$809-$163
Forex Effect-$7$9$27-$60
Net Chg. in Cash-$5,351-$383-$596-$1,582
Supplemental Information
Beg. Cash$7,400$7,783$8,378$9,960
End Cash$2,048$7,400$7,783$8,378
Free Cash Flow$740$837$909$1,055
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Financial Statements & Key Stats | AlphaPilot